| Nome |
# |
|
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells., file e27ce427-c7f3-2581-e053-d805fe0acbaa
|
367
|
|
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children, file e27ce42c-0323-2581-e053-d805fe0acbaa
|
316
|
|
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-76ff-2581-e053-d805fe0acbaa
|
258
|
|
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study, file e27ce42b-11e1-2581-e053-d805fe0acbaa
|
240
|
|
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B, file e27ce42d-32e8-2581-e053-d805fe0acbaa
|
204
|
|
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir, file e27ce428-c2c4-2581-e053-d805fe0acbaa
|
184
|
|
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy, file e27ce431-ddc8-2581-e053-d805fe0acbaa
|
125
|
|
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment?, file e27ce42f-24ff-2581-e053-d805fe0acbaa
|
115
|
|
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study, file e27ce432-20c9-2581-e053-d805fe0acbaa
|
113
|
|
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection, file e27ce42c-2693-2581-e053-d805fe0acbaa
|
112
|
|
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients, file e27ce42e-885a-2581-e053-d805fe0acbaa
|
97
|
|
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients, file e27ce431-312a-2581-e053-d805fe0acbaa
|
86
|
|
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2, file e27ce42f-e5ea-2581-e053-d805fe0acbaa
|
79
|
|
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon., file e27ce42a-709f-2581-e053-d805fe0acbaa
|
73
|
|
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients, file e27ce427-eef7-2581-e053-d805fe0acbaa
|
71
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42e-f730-2581-e053-d805fe0acbaa
|
71
|
|
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV, file e27ce431-312c-2581-e053-d805fe0acbaa
|
71
|
|
Data on the stability of darunavir/cobicistat suspension after tablet manipulation, file e27ce430-89c3-2581-e053-d805fe0acbaa
|
61
|
|
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients, file e27ce431-c868-2581-e053-d805fe0acbaa
|
60
|
|
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir., file e27ce427-eda3-2581-e053-d805fe0acbaa
|
51
|
|
A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring, file e27ce434-9e53-2581-e053-d805fe0acbaa
|
50
|
|
Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context, file e27ce432-e869-2581-e053-d805fe0acbaa
|
48
|
|
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., file e27ce427-ed9c-2581-e053-d805fe0acbaa
|
42
|
|
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma, file e27ce431-d047-2581-e053-d805fe0acbaa
|
40
|
|
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening, file e27ce431-e772-2581-e053-d805fe0acbaa
|
40
|
|
Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from “Integriamoci”, a Pilot Pharmacokinetic Study, file e27ce434-521e-2581-e053-d805fe0acbaa
|
38
|
|
Seasonal variation of antiretroviral drug exposure during the year: The experience of 10 years of therapeutic drug monitoring, file e27ce432-ff8c-2581-e053-d805fe0acbaa
|
37
|
|
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension, file e27ce428-a6ef-2581-e053-d805fe0acbaa
|
34
|
|
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy, file e27ce435-5bc4-2581-e053-d805fe0acbaa
|
33
|
|
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce435-8569-2581-e053-d805fe0acbaa
|
32
|
|
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma, file e27ce433-9ce4-2581-e053-d805fe0acbaa
|
31
|
|
Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma, file e27ce433-4ed5-2581-e053-d805fe0acbaa
|
24
|
|
Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections, file cf3e873d-3056-45c4-b40f-a348fd009f60
|
18
|
|
The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study, file e27ce435-4af8-2581-e053-d805fe0acbaa
|
14
|
|
Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series, file 421a7071-9ccb-4b67-b61d-620f87ab05cf
|
13
|
|
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy, file e27ce434-baaa-2581-e053-d805fe0acbaa
|
13
|
|
Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients, file e27ce433-9e71-2581-e053-d805fe0acbaa
|
12
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-accc-2581-e053-d805fe0acbaa
|
11
|
|
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes, file e27ce42b-fd4b-2581-e053-d805fe0acbaa
|
10
|
|
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants, file e27ce435-2ab2-2581-e053-d805fe0acbaa
|
9
|
|
Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease, file 3e8037dc-b65e-49e5-b58a-5dc1219b0f7e
|
8
|
|
Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in plasma: Implementation in a LC-MS/MS Kit, file 759e7a82-b9cd-484a-8443-c3076f5394e4
|
8
|
|
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms., file e27ce42a-7eca-2581-e053-d805fe0acbaa
|
8
|
|
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study, file e27ce42c-25e6-2581-e053-d805fe0acbaa
|
8
|
|
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration, file e27ce42e-f8ce-2581-e053-d805fe0acbaa
|
8
|
|
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce432-90a4-2581-e053-d805fe0acbaa
|
8
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-9d4e-2581-e053-d805fe0acbaa
|
7
|
|
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children, file e27ce42b-eb8d-2581-e053-d805fe0acbaa
|
6
|
|
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study, file e27ce42d-7321-2581-e053-d805fe0acbaa
|
6
|
|
Vitamin D impact in affecting clozapine plasma exposure: A potential contribution of seasonality, file 08f4348c-5e81-48e3-af06-87fe0ba6d762
|
5
|
|
Precision medicine for HIV: where are we?, file e27ce42c-8caa-2581-e053-d805fe0acbaa
|
5
|
|
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients, file e27ce42c-9b03-2581-e053-d805fe0acbaa
|
5
|
|
A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues, file 28ef6e89-e184-4891-b06e-f8e817f43700
|
4
|
|
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells, file e27ce428-bc7b-2581-e053-d805fe0acbaa
|
4
|
|
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon., file e27ce428-befb-2581-e053-d805fe0acbaa
|
4
|
|
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells., file e27ce428-ca8b-2581-e053-d805fe0acbaa
|
4
|
|
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients., file e27ce42a-7700-2581-e053-d805fe0acbaa
|
4
|
|
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B, file e27ce42a-e7bb-2581-e053-d805fe0acbaa
|
4
|
|
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients, file e27ce42b-d0ed-2581-e053-d805fe0acbaa
|
4
|
|
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma, file e27ce42b-ee07-2581-e053-d805fe0acbaa
|
4
|
|
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms, file e27ce42b-ee7b-2581-e053-d805fe0acbaa
|
4
|
|
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients, file e27ce42c-45f1-2581-e053-d805fe0acbaa
|
4
|
|
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis, file e27ce42d-0fbb-2581-e053-d805fe0acbaa
|
4
|
|
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy, file e27ce42d-7323-2581-e053-d805fe0acbaa
|
4
|
|
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples, file e27ce42d-8c34-2581-e053-d805fe0acbaa
|
4
|
|
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir., file e27ce432-2134-2581-e053-d805fe0acbaa
|
4
|
|
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients, file 07d108ff-0b30-4f3c-924f-3f11ae1321f3
|
3
|
|
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients, file e27ce426-fbb6-2581-e053-d805fe0acbaa
|
3
|
|
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells, file e27ce428-b957-2581-e053-d805fe0acbaa
|
3
|
|
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner., file e27ce428-ca85-2581-e053-d805fe0acbaa
|
3
|
|
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools., file e27ce42a-6f58-2581-e053-d805fe0acbaa
|
3
|
|
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors, file e27ce42c-1a28-2581-e053-d805fe0acbaa
|
3
|
|
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs, file e27ce42c-586b-2581-e053-d805fe0acbaa
|
3
|
|
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence, file e27ce42d-5e97-2581-e053-d805fe0acbaa
|
3
|
|
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients, file e27ce42d-5e98-2581-e053-d805fe0acbaa
|
3
|
|
Pharmacogenetic of voriconazole antifungal agent in pediatric patients, file e27ce42d-7320-2581-e053-d805fe0acbaa
|
3
|
|
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients, file e27ce42d-94fe-2581-e053-d805fe0acbaa
|
3
|
|
Flecainide plasma level modifications during the ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C, file e27ce430-a633-2581-e053-d805fe0acbaa
|
3
|
|
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting, file 0d6bcdd6-db3a-4898-9375-1fa250c44d79
|
2
|
|
Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis, file 10006f67-c420-470a-b4b7-2b93616d55dd
|
2
|
|
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients, file e27ce426-edae-2581-e053-d805fe0acbaa
|
2
|
|
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., file e27ce428-b3bf-2581-e053-d805fe0acbaa
|
2
|
|
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients, file e27ce428-bc16-2581-e053-d805fe0acbaa
|
2
|
|
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy, file e27ce428-c2bf-2581-e053-d805fe0acbaa
|
2
|
|
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens., file e27ce428-c7de-2581-e053-d805fe0acbaa
|
2
|
|
Pharmacogenetics of ribavirin-induced anemia in HCV patients, file e27ce42a-8fbd-2581-e053-d805fe0acbaa
|
2
|
|
UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients, file e27ce42a-b371-2581-e053-d805fe0acbaa
|
2
|
|
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma, file e27ce42a-c0ee-2581-e053-d805fe0acbaa
|
2
|
|
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump, file e27ce42b-2a7c-2581-e053-d805fe0acbaa
|
2
|
|
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4, file e27ce42b-6610-2581-e053-d805fe0acbaa
|
2
|
|
The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anemia in chronic hepatitis C Egyptian patients, file e27ce42b-e00b-2581-e053-d805fe0acbaa
|
2
|
|
Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect, file e27ce42b-e00e-2581-e053-d805fe0acbaa
|
2
|
|
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples, file e27ce42c-2cec-2581-e053-d805fe0acbaa
|
2
|
|
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples, file e27ce42c-3327-2581-e053-d805fe0acbaa
|
2
|
|
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration, file e27ce42c-8125-2581-e053-d805fe0acbaa
|
2
|
|
Cannabinoids concentration variability in cannabis olive oil galenic preparations, file e27ce42c-9627-2581-e053-d805fe0acbaa
|
2
|
|
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens, file e27ce42d-1f65-2581-e053-d805fe0acbaa
|
2
|
|
LC-MS application for therapeutic drug monitoring in alternative matrices, file e27ce42d-b625-2581-e053-d805fe0acbaa
|
2
|
|
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotics Supplementation, file e27ce430-93dc-2581-e053-d805fe0acbaa
|
2
|
|
Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients, file e27ce430-ae22-2581-e053-d805fe0acbaa
|
2
|
| Totale |
3.521 |